I too think that it is a possibility, but quite far from certain as most of the things on dia's list. I've listed some reasons on why I think a Bayer partnership could make sense, in post 186353. But that is only providing bavituximab + sorafenib Phase II data is worthy, otherwise we wouldn't get Bayer's attention.